Here are three things to know.
- Abilify Maintena is a once-daily injectable antipsychotic drug for intramuscular use.
- The agency first approved the drug in 2013 to treat schizophrenia.
- Abilify Maintena may now be used as a monotherapy for adults with bipolar I disorder.
More articles on supply chain:
Merck warns of drug delays after ‘NotPetya’ cyberattack: 3 things to know
6 must-reads for supply chain leaders this week
Drug packager recalls muscle spasm, Parkinson’s drugs over labeling errors
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
